Chordia Therapeutics is focused on developing innovative anti-cancer therapies that target RNA deregulation, a newly identified hallmark of cancer. Their research emphasizes the importance of understanding the mechanisms behind RNA regulation and its role in cancer progression. The company is advancing a pipeline of small molecule drugs designed to address various aspects of RNA maturation, including transcription, splicing, and RNA degradation. Key assets in their pipeline include the CLK inhibitor CTX-712, the MALT1 inhibitor CTX-177, the CDK12 inhibitor CTX-439, and the GCN2 inhibitor CRD-1968099, with several of these compounds currently undergoing clinical studies.

The approach taken by Chordia Therapeutics is rooted in solid scientific evidence and aims to establish personalized medicine strategies for cancer treatment. By collaborating with universities and research institutions that utilize next-generation sequencing and gene editing technologies, Chordia seeks to identify new therapeutic targets and enhance the efficacy of their drug candidates. Their focus on RNA deregulation as a stress phenotype in cancer highlights the potential for novel treatment options that could significantly improve outcomes for patients facing various types of cancer.

Japan

Chordia Therapeutics is a clinical-stage biotech company engaged in the research and development of novel therapies for cancers with high unmet medical needs. The Company was spun out from Takeda Pharmaceutical in November 2017.

Chordia Therapeutics

Company Details